Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States

被引：0
|
作者：
Sunnie Kim
James E. Signorovitch
Hongbo Yang
Oscar Patterson-Lomba
Cheryl Q. Xiang
Brian Ung
Monika Parisi
John L. Marshall
机构：
[1] MedStar Georgetown University Hospital,Ruesch Center for the Cure of GI Cancers
[2] Analysis Group,undefined
[3] Inc.,undefined
[4] Celgene Corporation,undefined
[5] Georgetown University,undefined
[6] Lombardi Comprehensive Cancer Center,undefined
来源：
Advances in Therapy | 2018年 / 35卷
关键词：
Adverse events; FOLFIRINOX; Metastatic adenocarcinoma of the pancreas; nab-Paclitaxel; Real-world evidence; Survival analysis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1564 / 1577
页数：13
相关论文
共 50 条
  • [21] Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting
    Braiteh, Fadi
    Patel, Manish B.
    Parisi, Monika
    Ni, Quanhong
    Park, Siyeon
    Faria, Claudio
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 141 - 148
  • [22] Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Whiting, Scott
    Binder, Gary
    Dranitsaris, George
    Manax, Victoria
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [23] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Jihoon Kang
    Inhwan Hwang
    Changhoon Yoo
    Kyu-pyo Kim
    Jae Ho Jeong
    Heung-Moon Chang
    Sang Soo Lee
    Do Hyun Park
    Tae Jun Song
    Dong Wan Seo
    Sung Koo Lee
    Myung-Hwan Kim
    Seung-Mo Hong
    Sang Hyun Shin
    Dae Wook Hwang
    Ki Byung Song
    Jae Hoon Lee
    Song Cheol Kim
    Baek-Yeol Ryoo
    Investigational New Drugs, 2018, 36 : 732 - 741
  • [24] Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
    Kang, Jihoon
    Hwang, Inhwan
    Yoo, Changhoon
    Kim, Kyu-pyo
    Jeong, Jae Ho
    Chang, Heung-Moon
    Lee, Sang Soo
    Park, Do Hyun
    Song, Tae Jun
    Seo, Dong Wan
    Lee, Sung Koo
    Kim, Myung-Hwan
    Hong, Seung-Mo
    Shin, Sang Hyun
    Hwang, Dae Wook
    Song, Ki Byung
    Lee, Jae Hoon
    Kim, Song Cheol
    Ryoo, Baek-Yeol
    INVESTIGATIONAL NEW DRUGS, 2018, 36 (04) : 732 - 741
  • [25] nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life
    Cidon, E. Una
    Alonso, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S109 - S109
  • [26] Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer
    Filipazzi, V.
    Dalu, D.
    Isabella, L.
    Tosca, N.
    Ferrario, S.
    Gambaro, A.
    Somma, L.
    Fasola, C.
    Pellegrini, I.
    Bombonati, G.
    Curcio, R.
    Damiani, E.
    Cattaneo, M. T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [27] FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure
    Matsumoto, Toshihiko
    Kurioka, Yusuke
    Okazaki, Ukyo
    Matsuo, Yu
    Kimura, Shogo
    Miura, Kou
    Tsuduki, Takao
    Takagi, Shinjiro
    Takatani, Masahiro
    Morishita, Hirofumi
    PANCREAS, 2020, 49 (04) : 574 - 578
  • [28] Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel
    Ide, Yasushi
    Otsuka, Taiga
    Shimokawa, Mototsugu
    Koga, Futa
    Ueda, Yujiro
    Nakazawa, Junichi
    Komori, Azusa
    Otsu, Satoshi
    Arima, Shiho
    Fukahori, Masaru
    Makiyama, Akitaka
    Shinohara, Yudai
    Ueno, Shohei
    Taguchi, Hiroki
    Honda, Takuya
    Shibuki, Taro
    Nio, Kenta
    Ureshino, Norio
    Mizuta, Toshihiko
    Mitsugi, Kenji
    Shirakawa, Tsuyoshi
    ANTICANCER RESEARCH, 2023, 43 (04) : 1817 - 1826
  • [29] Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma after failure of nab-paclitaxel plus gemcitabine.
    Ozaka, Masato
    Sasaki, Takashi
    Kataoka, Seita
    Kanata, Ryo
    Ishigaki, Kazunaga
    Yamada, Ikuhiro
    Matsuyama, Masato
    Takano, Koichi
    Sasahira, Naoki
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [30] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
12345